{'fraction_non_alphanumeric': 0.030303030303030304, 'fraction_numerical': 0.006060606060606061, 'mean_word_length': 5.814432989690721, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Bone marrow scintigraphy. Principles, clinical results and indications].

After consideration of the anatomical and physiological principles, the radiopharmaceuticals for scintigraphy of the erythropoietic, reticuloendothelial and-as a new development-of the granulopoietic bone marrow are introduced and compared. The data on performing and evaluating bone marrow scans are followed by the presentation of the clinical results. Staging and re-staging of malignant lymphomas, multiple myeloma, breast and lung cancer are considered to be the main indications. 99mTc-labelled monoclonal anti-NCA-95-antibodies are regarded as the radiopharmaceutical of choice.